Both ECM‐targeting agents significantly delayed tumor regrowth compared to BRAF/MEKi alone, as defined by the time required for tumors to return to their pre‐treatment volume (≈700 mm3) (Figure 4B,C; Figure S4A, Supporting Information). The gene discussed is BRAF; the disease is neoplasm.